Expert Discusses Uncertainty Over Ideal IP Chemo Approach in Ovarian Cancer (GOG 252) Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Wednesday, January 25, 2017

Expert Discusses Uncertainty Over Ideal IP Chemo Approach in Ovarian Cancer (GOG 252)



interview
Monday, Jan 23, 2017
The much anticipated initial results of the Gynecologic Oncology Group (GOG) 252 trial failed to provide additional clarity for the use of intravenous (IV) versus intraperitoneal (IP) chemotherapy in patients with ovarian cancer, explains Franco M. Muggia, MD.

0 comments :

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.